Oveporexton

DB21680ApprovedSmall molecule

Oveporexton is an oral orexin receptor 2 (OX2R)-selective agonist indicated for narcolepsy type 1 in adults, restoring deficient orexin signaling to promote wakefulness and reduce cataplexy and other REM-sleep-related symptoms. NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other REM-sleep-related symptoms.

Chemical structure of Oveporexton
Mechanism
Curator reviewed
Primary indication
Oveporexton is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.Curator reviewed · 1 structured indication
Formula / weight
C23H25F5N2O4S · 520.52 g/mol (avg)
Code names
TAK-861

Resolves to

Clinical / RWD
Structure
InChIKeyKVMGAIOTUIGROS-AZUAARDMSA-NSMILESCCS(=O)(=O)N[C@@H]1[C@H](CC2=CC=CC(=C2F)C2=CC(F)=CC(F)=C2)N(CC1(F)F)C(=O)C(C)(C)O

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4TransportersSubstrate / inhibitor direction, not just membership
Listed above
115Drug interactionsStructured to mechanism, not free text
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Oveporexton, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account